Search
Hypertension Paid Clinical Trials in Pennsylvania
A listing of 40 Hypertension clinical trials in Pennsylvania actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 40
The state of Pennsylvania currently has 40 active clinical trials seeking participants for Hypertension research studies. These trials are conducted in various cities, including Philadelphia, Pittsburgh, Hershey and Allentown.
Featured Trial
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
High Triglyceride Clinical Research Study
Recruiting
Living with high triglycerides? See if our clinical study is right for you.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.
Conditions:
High Triglycerides
High Triglyceride Level
Hypertriglyceridemia
Elevated Triglycerides
Triglycerides High
Featured Trial
Heart Failure Clinical Trial
Recruiting
You or someone you love may be eligible for a heart failure clinical study. Eligible participants will receive study-related assessments, care, and treatment at no cost. You may be reimbursed for travel while participating. See if you are eligible.
Conditions:
Heart Failure
Congestive Heart Failure
Chronic Heart Failure
Heart Failure
Congestive
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
Recruiting
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg Baxdrostat vs. placebo, administered QD orally, on the reduction of SBP, measured by average 24-hour ABPM in 212 participants with rHTN (defined as seated SBP ≥ 140 mmHg at Screening and mean ambulatory SBP ≥ 130 mmHg at baseline, despite a stable regimen of ≥ 3 antihypertensive agents, one of which is a diuretic).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/17/2025
Locations: Research Site, Langhorne, Pennsylvania
Conditions: Resistant Hypertension
A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12)
Recruiting
This study is being conducted to assess the long-term safety, tolerability, and efficacy of sotatercept (MK-7962, formerly called ACE-011) in participants with Pulmonary Arterial Hypertension (PAH). This open-label, long-term follow-up (LTFU) study is supported by data from the PULSAR study (Phase 2, NCT03496207) in which treatment with sotatercept resulted in hemodynamic and functional improvements in the study participants, including those receiving maximal PAH therapy with double/triple drug... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/16/2025
Locations: UPMC Presbyterian. UPMC Presbyterian Hospital ( Site 1059), Pittsburgh, Pennsylvania
Conditions: PAH, Pulmonary Arterial Hypertension
Feasibility of Semaglutide in Advanced Lung Disease
Recruiting
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease.
The main question\[s\] it aims to answer are:
1. Are patients with advanced lung disease able to tolerate semaglutide therapy?
2. Are we able to titrate semaglutide therapy to a target weight?
Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a bl... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/13/2025
Locations: University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
Conditions: Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension
Autologous Stem Cell Transplantation in Patients with Systemic Sclerosis
Recruiting
The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.
Gender:
ALL
Ages:
Between 8 years and 60 years
Trial Updated:
03/13/2025
Locations: Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania +2 locations
Conditions: Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
Clarifying the Optimal Application of SLT Therapy Trial
Recruiting
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Eye Care Specialists, Kingston, Pennsylvania +3 locations
Conditions: Glaucoma and Ocular Hypertension
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Recruiting
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Gender:
ALL
Ages:
Between 0 years and 20 years
Trial Updated:
03/11/2025
Locations: Pennsylvania State University--Hershey Children's Hospital, Hershey, Pennsylvania
Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Hemophilia, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: St. Luke's University Health Network, Bethlehem, Pennsylvania
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
Recruiting
Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is different than pulmonary hypertension in adults and this study will help us understand those differences.
Gender:
ALL
Ages:
Between 1 day and 21 years
Trial Updated:
03/10/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
LEVosimendan to Improve Exercise Limitation in Patients with PH-HFpEF
Recruiting
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/07/2025
Locations: Tenax Investigational Site, Philadelphia, Pennsylvania +1 locations
Conditions: Pulmonary Hypertension
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
Recruiting
A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure pacemaker.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania +1 locations
Conditions: Hypertension, Hypertension, Systolic, Hypertension, Essential
Metformin for Pulmonary Hypertension HFpEF
Recruiting
The main objective of this study is to determine the clinical efficacy of metformin versus placebo and the therapeutic response with regards to functional capacity and hemodynamics in PH-HFpEF.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Pulmonary Hypertension, Heart Failure
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Recruiting
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania +3 locations
Conditions: PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
1 - 12 of 40